Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA.
Janssen Research & Development, Beerse, Belgium.
Influenza Other Respir Viruses. 2022 Sep;16(5):906-915. doi: 10.1111/irv.12994. Epub 2022 Apr 26.
Influenza and respiratory syncytial virus (RSV) are associated with substantial morbidity and mortality in the United States. We assessed risk factors for severe disease and medical resource utilization (MRU) among US adults hospitalized with influenza or RSV in the Hospitalized Acute Respiratory Tract Infection (HARTI) study.
HARTI was a prospective global (40 centers, 12 countries) epidemiological study of adults hospitalized with acute respiratory tract infections conducted across the 2017-2019 epidemic seasons. Patients with confirmed influenza or RSV were followed up to 3 months post-discharge. Baseline characteristics, prevalence of core risk factors (CRFs) for severe disease (age ≥65 years, chronic heart or renal disease, chronic obstructive pulmonary disease, or asthma), and MRU were summarized descriptively.
The US cohort included 280 influenza-positive and 120 RSV-positive patients. RSV patients were older (mean: 63.1 vs. 59.7 years) and a higher proportion had CRFs (87.5% vs. 81.4%). Among those with CRFs (influenza, n = 153; RSV, n = 99), RSV patients required longer hospitalizations (median length of stay: 4.5 days) and a greater proportion (79.8%) required oxygen supplementation during hospitalization compared with influenza patients (4.0 days and 59.5%, respectively). At 3 months post-discharge, a greater proportion of RSV patients with CRFs reported use of antibiotics, antitussives, bronchodilators, and inhaled and systemic steroids versus those with influenza and CRFs. Many patients with CRFs reported hospital readmission at 3 months post-discharge (RSV: 13.4%; influenza: 11.9%).
MRU during and post-hospitalization due to RSV in adults is similar to or greater than that of influenza. Enhanced RSV surveillance and preventive and therapeutic interventions are needed.
流感和呼吸道合胞病毒(RSV)在美国会导致大量发病和死亡。我们评估了美国因流感或 RSV 住院的成年人发生严重疾病和医疗资源利用(MRU)的风险因素,研究来自 Hospitalized Acute Respiratory Tract Infection(HARTI)研究。
HARTI 是一项前瞻性的全球性(40 个中心,12 个国家)成人急性呼吸道感染住院患者的流行病学研究,横跨 2017-2019 年流行季进行。对确诊流感或 RSV 的患者进行随访,直至出院后 3 个月。对患者的基线特征、严重疾病(年龄≥65 岁、慢性心脏或肾脏疾病、慢性阻塞性肺疾病或哮喘)核心风险因素(CRF)的患病率以及 MRU 进行描述性总结。
美国队列纳入 280 例流感阳性和 120 例 RSV 阳性患者。RSV 患者年龄较大(平均年龄:63.1 岁 vs. 59.7 岁),且有更多的 CRF(87.5% vs. 81.4%)。在有 CRF 的患者中(流感,n=153;RSV,n=99),RSV 患者的住院时间更长(中位住院时间:4.5 天),需要住院期间吸氧的比例也更高(79.8% vs. 59.5%)。出院后 3 个月时,更多有 CRF 的 RSV 患者报告使用抗生素、镇咳药、支气管扩张剂以及吸入和全身皮质类固醇,而非有 CRF 的流感患者。许多有 CRF 的患者在出院后 3 个月时报告再次住院(RSV:13.4%;流感:11.9%)。
成人因 RSV 住院期间和出院后的 MRU 与流感相似或更高。需要加强 RSV 监测以及预防和治疗干预。